| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 08/26/2008 | CA2361614C Compositions for treating inflammatory response |
| 08/26/2008 | CA2347474C Bicyclic nitrogen heterocycles |
| 08/26/2008 | CA2312021C Use of ketolides for preparing arterial thrombotic complications related to atherosclerosis |
| 08/26/2008 | CA2277112C Use of exendins and agonists thereof for the reduction of food intake |
| 08/26/2008 | CA2274825C Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase |
| 08/26/2008 | CA2239780C A process for regulating vagal tone |
| 08/21/2008 | WO2008101012A1 Use of ranolazine for the treatment of non-coronary microvascular diseases |
| 08/21/2008 | WO2008101008A1 Use of ranolazine for the treatment of coronary microvascular diseases |
| 08/21/2008 | WO2008101002A1 Use of ranolazine for the treatment of cardiovascular diseases |
| 08/21/2008 | WO2008100803A1 Antihypertensive drug combination |
| 08/21/2008 | WO2008100635A1 1- [3- (monocyclic amino) propyl] - 4, 5, 6, 7-tetrahydro-1h-pyrazolo [4, 3-c] -pyridines as modulators of cathepsin s |
| 08/21/2008 | WO2008100453A1 Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
| 08/21/2008 | WO2008099928A1 Placental protein having action of regulating protease activity and its related gene |
| 08/21/2008 | WO2008099912A1 5ht4 receptor antagonist |
| 08/21/2008 | WO2008099908A1 Vaccine therapy for choroidal neovascularization |
| 08/21/2008 | WO2008099883A1 Therapeutic agent for liver cancer |
| 08/21/2008 | WO2008099805A1 Central circulation-improving agent |
| 08/21/2008 | WO2008099396A1 Use of h19-silencing nucleic acid agents for treating restenosis |
| 08/21/2008 | WO2008099186A1 Heterocyclic derivatives as m3 muscarinic receptors |
| 08/21/2008 | WO2008099025A2 Body-weight maintenance and body composition |
| 08/21/2008 | WO2008098992A1 Use of organic compounds |
| 08/21/2008 | WO2008098427A1 Use of ethyl piperic acid ester in preparation of medicament or healthcare product for the prevention and/or treatment of atherosclerosis |
| 08/21/2008 | WO2008075349B1 Therapeutic methods using a thymus peptide |
| 08/21/2008 | WO2008063795A9 Biological pacemaker compositions and systems incorporating interstitial cells of cajal |
| 08/21/2008 | WO2007088418A9 Drug-eluting intravascular prostheses and methods of use |
| 08/21/2008 | US20080200674 Anticoagulants; cardiovascular disorders; atherosclerosis; antiarthritic agents;Alzheimer's disease; anticancer agents |
| 08/21/2008 | US20080200646 and cerebral ischemia and or the onset of systemic inflammatory response particularly when associated with a surgical procedure(especially cardiothoracic surgery; kit comprising a dry lyophilized kallikrein inhibitor DX88 in a hermetically sealed container (rather than aprotinin) |
| 08/21/2008 | US20080200566 Dephosphorylation of HDAC7 By Myosin Phosphatase |
| 08/21/2008 | US20080200553 N-[2-Chloro-4-pentafluorosulfanylbenzoyl]guanidine; ischemia, reperfusion, arrythmia angina pectoris; inhibit the cellular sodium-proton antiporter (Na+/H+ exchanger, NHE); stability, longer half-life in vivo, high bioavailability |
| 08/21/2008 | US20080200547 Highly Purified Ethyl EPA and Other EPA Derivatives |
| 08/21/2008 | US20080200529 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels |
| 08/21/2008 | US20080200495 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof |
| 08/21/2008 | US20080200494 Imidazopyridine Derivatives |
| 08/21/2008 | US20080200491 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel |
| 08/21/2008 | US20080200484 Pharmaceutical Compositions Comprising A Multifunctional Phosphodiesterase Inhibitor and An Adenosine Uptake Inhibitor |
| 08/21/2008 | US20080200481 Method of treatment of myocardial infarction |
| 08/21/2008 | US20080200475 platelet dependent thrombosis; P2Y12 receptor antagonists; Ethyl N-[({4-[4-(1,1'-biphenyl-4-ylcarbonyl)piperazin-1-yl]-6-ethylthieno[- 2,3-d]pyrimidin-2-yl}amino)carbonyl]glycinate |
| 08/21/2008 | US20080200467 alpha keto amides and alpha hydroxy amides; N-[3-(3-Morpholin-4-yl-propoxy)-phenyl]-2-oxo-2-(4-trifluoromethyl-phenyl)-acetamide; N-Adamantan-1-yl-2-(3-benzyloxyphenyl)-2-hydroxy-acetamide; hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases |
| 08/21/2008 | US20080200463 N-[5-(5-formyl-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide; autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer |
| 08/21/2008 | US20080200446 1,4-Diphenyl-3-substituted azetidin-2-ones; can be metabolized in vivo to form a sterol and/or stanol absorption inhibitor and a sterol biosynthesis inhibitor for treatment of atherosclerosis, hypercholesterolemia, or sitosterolemia |
| 08/21/2008 | US20080200445 Heterocyclic aspartyl protease inhibitors |
| 08/21/2008 | US20080200439 Establishing a test sample comprising a myocyte BK channel beta 1 subunit and measuring the interaction, effect, or combination thereof, of a candidate composition on test sample to thereby determine ability of candidate composition to modulate myocyte BK channel activity |
| 08/21/2008 | US20080200420 Engineered RNA precursors encoded in plasmids and/or other vectors; simple, low cost technique utilizing DNA molecule production; host cells, transgenes |
| 08/21/2008 | US20080200407 Suppress the immunoreactivity of a CpG motif and preventing and treating immune-mediated diseases such as arthritis |
| 08/21/2008 | US20080200393 Treat disease associated with substrate-phosphorylation by VEGF receptor, substrate-phosphorylation by PDGF receptor or substrate-phosphorylation by both VEGF and PDGF receptors |
| 08/21/2008 | US20080200391 Stimulating differentiation in growth of osteoblasts and osteoclasts; wound healing of bone fractures and de novo bone formation; osteoporosis; bone cancer treatment; polynucleotide encoding polypeptide; genetic engineering |
| 08/21/2008 | US20080200376 Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction |
| 08/21/2008 | US20080200375 Treating vascular insufficiency or limb ischemia secondary to arterial occlusive disease; kits |
| 08/21/2008 | US20080200371 Thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| 08/21/2008 | US20080199865 Using allelic variation in interleukin-1RN variable number of tandem repeats as diagnostic/prognostic indicator of decrease cell division and aging characteristics |
| 08/21/2008 | US20080199547 Berry Oils and Products |
| 08/21/2008 | US20080199543 Pharmaceutically Active Extracts of Vitex Leucoxylon, a Process of Extracting the Same and a Method of Treating Diabetes and Inflammatory Diseases Therewith |
| 08/21/2008 | US20080199532 Congestive heart failure; induce vasodilation |
| 08/21/2008 | US20080199505 Local Gene Therapy with an Eluting Stent for Vascular Injury |
| 08/21/2008 | US20080199504 Dynamers for therapeutic agent delivery applications |
| 08/21/2008 | US20080199503 Mixture of oligopeptide and cyclodextrins; model for drug design ; hypotensive agenst; cardiovascular disorders; atherosclerosis; antitumor agenst; antidiabetic agenst |
| 08/21/2008 | US20080199473 Novel Gene and Protein Associated With Angiogenesis and Endothelial Cell-Specific Apoptosis |
| 08/21/2008 | US20080199454 Caspase inhibitor prodrugs |
| 08/21/2008 | US20080199449 Methods and Compositions for Use in Treating Vascular Diseases and Conditions |
| 08/21/2008 | US20080199445 Compositions and methods for treatment of microbial infections |
| 08/21/2008 | US20080199441 Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases |
| 08/21/2008 | US20080199435 IL-8 Like Protein |
| 08/21/2008 | US20080199434 Compositions and methods for the treatment of cardiovascular conditions |
| 08/21/2008 | US20080199426 Administering compound which inhibits tie-1 protein, thrombin, growth factors; increases activity of nitric oxide synthase; arteriosclerosis, sepsis, rheumatoid arthritis and pre-eclampsia |
| 08/21/2008 | CA2679849A1 Functionally selective alpha2c adrenoreceptor agonists |
| 08/21/2008 | CA2678432A1 Vaccine therapy for choroidal neovascularization |
| 08/21/2008 | CA2678325A1 Use of ranolazine for the treatment of non-coronary microvascular diseases |
| 08/21/2008 | CA2678319A1 Use of ranolazine for the treatment of coronary microvascular diseases |
| 08/21/2008 | CA2678127A1 Tgf-beta stimulant and further agent to reduce side effects |
| 08/21/2008 | CA2678036A1 Functionally selective alpha2c adrenoreceptor agonists |
| 08/21/2008 | CA2677931A1 Use of ranolazine for the treatment of cardiovascular diseases |
| 08/21/2008 | CA2677822A1 Antihypertensive drug combination |
| 08/21/2008 | CA2677747A1 Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
| 08/21/2008 | CA2676581A1 Heterocyclic derivatives as m3 muscarinic receptors |
| 08/20/2008 | EP1959013A1 Human circulating virus inhibitory peptide (VRIP) and its use |
| 08/20/2008 | EP1958941A1 Oxazolidinones and their use as hypocholesterolemic agents |
| 08/20/2008 | EP1958937A1 Delta d Crystaline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same |
| 08/20/2008 | EP1958522A2 Functional food having positive effects in the prevention of cardiovascular diseases |
| 08/20/2008 | EP1957490A1 Novel indolizine derivatives, method for preparing same and therapeutic compositions comprising same |
| 08/20/2008 | EP1957081A1 Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid |
| 08/20/2008 | EP1957064A2 Treatment of qt interval prolongation and diseases associated therewith |
| 08/20/2008 | EP1957057A1 Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status |
| 08/20/2008 | EP1666880B1 Screening method |
| 08/20/2008 | EP1616873B1 Lipid-regulating agent and use thereof |
| 08/20/2008 | EP1509618B1 Autoimmune conditions and nadph oxidase defects |
| 08/20/2008 | EP1482935B1 Thiazole and oxazole derivatives which modulate ppar activity |
| 08/20/2008 | EP1456203B1 Ethylene diamine derivatives and their use as orexin-receptor antagonists |
| 08/20/2008 | EP1451202B1 Aryl fused azapolycyclic compounds |
| 08/20/2008 | EP1404653B1 Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| 08/20/2008 | EP1318993B1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 08/20/2008 | EP1289993B9 Caspase inhibitors and uses thereof |
| 08/20/2008 | EP1282429B1 Pharmaceutical gel composition |
| 08/20/2008 | EP1240823B1 N-calcium channel knockout animal |
| 08/20/2008 | EP1198589B1 Tenascin-c nucleic acid ligands |
| 08/20/2008 | EP1075493B1 Dna encoding snorf25 receptor |
| 08/20/2008 | EP1045918B1 G protein-related kinase mutants in essential hypertension |
| 08/20/2008 | EP0703897B1 Lipoxin compounds with prolonged half-life |
| 08/20/2008 | CN101248171A Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
| 08/20/2008 | CN101248065A Activator of peroxisome proliferator activated receptor delta |
| 08/20/2008 | CN101248062A C-fms kinase inhibitors |